27 August 2021>: Clinical Research
A Prognostic Model of Gastrointestinal Diffuse Large B Cell Lymphoma
Fan Gao 1ACDEF , Zhan-fang Wang 2BCD , Lei Tian 1DF , Fei Dong 1BC , Jing Wang 1BD , Hong-mei Jing 1BD , Xiao-yan Ke 1AG*DOI: 10.12659/MSM.929898
Med Sci Monit 2021; 27:e929898
Table 1 Patient information and 3-year survival rate.
Clinical features | Number and proportion of patients | Number and proportion of patients that survived | χ2 | p-value |
---|---|---|---|---|
Total | 82 | 48 (58.5%) | ||
Age (years) | ||||
≤60 | 33 (40.2%) | 24 (72.7%) | 9.0162 | 0.01102 |
Between 60–75 | 34 (41.5%) | 20 (58.5%) | ||
>75 | 15 (18.3%) | 4 (26.6%) | ||
Gender | ||||
Male | 45 (54.9%) | 27 (60.0%) | 0.0051 | 0.9431 |
Famale | 37 (45.1%) | 21 (56.8%) | ||
PGL | ||||
Yes | 38 (46.3%) | 28 (73.6%) | 5.5823 | 0.01814 |
No | 44 (53.7%) | 20 (45.5%) | ||
Region involved | ||||
Stomach | 42 (51.2%) | 28 (66.7%) | 0.2002 | |
Small intestine | 12 (14.6%) | 4 (33.3%) | ||
Ileocecum | 14 (17.1%) | 8 (57.1%) | ||
Colon | 4 (4.9%) | 1 (25.0%) | ||
Rectum | 1 (1.2%) | 1 (100%) | ||
Multiple sites | 9 (11.0%) | 6 (66.7%) | ||
Symptoms | ||||
Asymptomatic | 6 (7.3%) | 3 (50.0%) | 0.7485 | |
Non-specific symptoms | 58 (70.7%) | 33 (56.9%) | ||
Specific symptoms | 18 (22.0%) | 12 (66.7%) | ||
Pre-treatment complications | ||||
Yes | 33 (40.2%) | 17 (51.5%) | 0.68985 | 0.4062 |
Bleeding | 20 (24.4%) | 12 (60.0%) | ||
Perforation | 0 (0.0%) | 0 (0.0%) | ||
Obstruction | 13 (15.9%) | 4 (30.8%) | ||
Intussusception | 5 (0.06%) | 3 (60.0%) | ||
No | 49 (59.8%) | 31 (63.2%) | ||
Post-treatment complications | ||||
Yes | 14 (17.1%) | 4 (28.6%) | 4.8455 | 0.02772 |
No | 68 (82.9%) | 44 (64.7%) | ||
Pathological subtype | ||||
ABC | 38 (46.3%) | 21 (55.3%) | 0.34074 | 0.8434 |
GCB | 24 (29.3%) | 15 (62.5%) | ||
Not classified | 20 (24.4%) | 12 (60.0%) | ||
Bcl2 | ||||
Positive | 30 (36.6%) | 12 (40.0%) | 2.9881 | 0.08388 |
Negative | 22 (26.8%) | 15 (68.2%) | ||
Bcl6 | ||||
Positive | 34 (41.5%) | 21 (61.8%) | 0.53684 | 0.4637 |
Negative | 34 (41.5%) | 17 (50.0%) | ||
Ann Arbor stage | ||||
I | 17 (20.7%) | 14 (82.4%) | 0.04476 | |
II | 14 (17.1%) | 10 (71.4%) | ||
III | 9 (11.0%) | 5 (55.6%) | ||
IV | 42 (51.2%) | 19 (45.2%) | ||
IPI score | ||||
0 | 9 (11.1%) | 8 (88.9%) | 0.01874 | |
1 | 13 (15.9%) | 8 (61.5%) | ||
2 | 17 (20.7%) | 13 (76.4%) | ||
3 | 15 (18.3%) | 6 (40.0%) | ||
4 | 20 (24.4%) | 8 (40.0%) | ||
5 | 2 (2.4%) | 0 (0.0%) | ||
Types of ulcers | ||||
No ulcer | 22 (26.8%) | 9 (40.9%) | 0.02365 | |
Simple ulcer | 30 (36.6%) | 24 (80.0%) | ||
Multiple ulcers | 12 (14.6%) | 6 (50.0%) | ||
Giant Ulcer | 13 (15.9%) | 7 (53.8%) | ||
Endoscopic findings | ||||
Mucosal erythema/benign-appearing gastric ulcer | 48 (58.5%) | 31 (64.6%) | 1.5733 | 0.4554 |
Thickened or diffuse bulge | 15 (18.3%) | 7 (46.7%) | ||
Mass | 14 (%) | 8 (57.1%) | ||
PGL – primary gastrointestinal lymphoma; specific symptoms include hematemesis, blood in the stool, melena, and cessation of exhaustion; ABC – activated B cell type; GCB – germinal center B cell type. |